Cognition Therapeutics, Inc. Common Stock (CGTX) is a publicly traded Healthcare sector company. As of May 21, 2026, CGTX trades at $1.25 with a market cap of $97.55M and a P/E ratio of -3.98. CGTX moved +15.32% today. Year to date, CGTX is -7.86%; over the trailing twelve months it is +281.43%. Its 52-week range spans $0.22 to $3.83. Analyst consensus is buy with an average price target of $3.50. Rallies surfaces CGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cognition Therapeutics Secures FDA Path Forward for Zervimesine Registrational DLB Psychosis Study: Cognition Therapeutics completed a May 20 FDA meeting to review Phase 2 SHIMMER results for its oral zervimesine and discuss registrational study design and endpoints for dementia with Lewy bodies psychosis. The company expects formal FDA meeting minutes in June to confirm the path forward for late-stage program.
| Metric | Value |
|---|---|
| Price | $1.25 |
| Market Cap | $97.55M |
| P/E Ratio | -3.98 |
| EPS | $-0.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.83 |
| 52-Week Low | $0.22 |
| Volume | 34.92K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-23.49M |
| Gross Margin | 0.00% |
2 analysts cover CGTX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.50.